bioihbjkbjnl/mcl2 huggingface dataset:
Far Forward Battlefield Telemedicine: Evaluation of Handheld Ultrasound
Condition: Thoracic Injuries
MeSH terms: Thoracic Injuries
Study type: Observational

Summary: 
      The goal of this study is to improve survival of battlefield trauma through ultrasound
      telemedicine and remotely guided therapeutics.
    

Detailed description: 
      Specific aims to meet to improve the survival of battlefield trauma are 1)validation of
      portable ultrasound for diagnosis of various medical and surgical emergencies, ie cardiac
      tamponade, intraabdominal hemorrhage, 2)Extension of our expertise in digital
      echocardiography and local telemedicine to support other centers in such procedures as TEE
      3)development of wireless telemedicine systems for rapid relay of ultrasonic images from
      portable ultrasound system to a remote review station. 4)development of a precision guide for
      diagnostic and therapeutic percutaneous procedures using ultrasound guidance 5)combining
      wireless telemetry with the guided percutaneous access tool to permit remotely guided
      emergency procedures 6)augmenting this work(2D/echo) with 3D/echo.
    

Intervention name(s): Miniature echo machine
Intervention type(s): Device
Intervention description(s): Images captured and real-time and store-and-forward file transfers performed
Observational model: Other
Time perspective: Cross-Sectional
Sampling method: Non-Probability Sample
Study population: 
        Patients scheduled for clinical echocardiographic study Patients with possible diagnosis of
        cardiac tamponade
      
Keywords: trauma; portable ultrasound; telemedicine; Department of Defense
Efficacy and Safety of Plasma Exchange With Albumin in Patients With Amyotrophic Lateral Sclerosis
Condition: Amyotrophic Lateral Sclerosis
MeSH terms: Motor Neuron Disease; Amyotrophic Lateral Sclerosis; Sclerosis
Study type: Interventional
Phase: Phase 2

Summary: 
      Pilot, phase II, prospective, open-label, uncontrolled study of plasma exchange with 5%
      albumin in 10 subjects having a definite, possible, or probable diagnosis of Amyotrophic
      Lateral Sclerosis (ALS).
    


Intervention name(s): Albumin
Intervention type(s): Biological
Intervention description(s): 27 plasma exchange procedures using Albumin 5% (estimated 3000 mL per plasma exchange) as replacement solution:
three weeks of intensive treatment with two plasma exchanges per week
twenty-one weeks of maintenance treatment with one weekly plasma exchange
Other intervention name(s): Human Albumin 5%; Albutein 5%
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: plasma exchange; albumin
Web-Based Self-Monitoring Activity-Restriction and Relaxation Training Program for Kids With Mild Traumatic Brain Injury
Condition: Brain Injury Traumatic Mild
MeSH terms: Brain Injuries; Brain Injuries, Traumatic; Wounds and Injuries
Study type: Interventional

Summary: 
      SMART is an interactive web-based program that will allow youth with mild traumatic brain
      injuries (mTBI) to monitor their symptoms and receive education on problem-solving and coping
      strategies. This study will evaluate the effectiveness of SMART as a means of improving
      symptom-management, coping skills, and general well-being during recovery from mTBI. Half of
      participants will receive the SMART intervention, while half will receive usual care.
    


Intervention name(s): Self-Monitoring Activity-restriction and Relaxation Training (SMART)
Intervention type(s): Behavioral
Intervention description(s): SMART integrates real-time self-monitoring of symptoms and activities with interactive modules designed to increase self-efficacy through psychoeducation and training in problem solving/problem-focused coping strategies.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Supportive Care
Effects of Cognitive Intervention for Older Adults With Memory Decline: A Pilot Study
Condition: Mild Cognitive Impairment
MeSH terms: Cognitive Dysfunction
Study type: Interventional
Phase: Phase 1

Summary: 
      The purpose of this study is to evaluate the effects of training in memory skills vs. use of
      external memory aids on everyday memory functioning in older people with mild cognitive
      impairment.
    

Detailed description: 
      Some older people experience memory loss that is worse than other people of their age,
      although they are not demented. This condition is known as mild cognitive impairment (MCI).
      Healthy older people can learn mnemonic strategies to improve their memory abilities. Can
      cognitive rehabilitation help people with MCI do better on mental tasks or maintain better
      functioning in everyday life? This study will evaluate the effects of two different
      rehabilitation programmes. Patients in the memory training group will learn mental strategies
      aimed at improving memory. Patients in the memory compensation group will learn to use
      external memory aids.
    

Intervention name(s): MEMO programme (Inst Universitaire de Geriatrie, Montreal); External memory aids training
Intervention type(s): Behavioral; Behavioral
Intervention description(s): 8 weekly group training sessions in mnemonic strategies, administered by clinical psychologist.; 8 weekly group sessions of training in the use of external memory aids, administered by clinical psychologist
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: cognitive training; cognitive rehabilitation
A Phase I Safety Study of NVG-291 in Healthy Adults
Condition: Spinal Cord Injury
MeSH terms: Spinal Cord Injuries
Study type: Interventional
Phase: Phase 1

Summary: 
      This is a randomized, triple-blind (subjects, Investigators, and Sponsor blinded),
      placebo-controlled Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) study to
      evaluate the safety and tolerability of NVG-291 administered by subcutaneous injection daily
      in healthy female participants. The trial is split into three parts, starting with Part 1
      (SAD), then Part 2 (MAD - post-menopausal Females), and finally Part 3 (MAD - males and
      premenopausal females). In Part 1 (SAD), participants receive 1 dose on 1 day only and in
      Parts 2 and 3, participants receive 1 dose every day for 14 days.
    


Intervention name(s): NVG-291; Placebo
Intervention type(s): Drug; Other
Intervention description(s): NVG-291 is a drug injected under the skin (subcutaneous).; Salt water is being used as a placebo and will be injected under the skin (subcutaneous).
Allocation: Randomized
Intervention model: Sequential Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary purpose: Treatment
FX-322 in Adults With Acquired Sensorineural Hearing Loss
Condition: Hearing Loss, Sensorineural; Noise Induced Hearing Loss; Sudden Hearing Loss
MeSH terms: Hearing Loss; Deafness; Hearing Loss, Sensorineural; Hearing Loss, Noise-Induced; Hearing Loss, Sudden
Study type: Interventional
Phase: Phase 2

Summary: 
      This is a Phase 2, prospective, randomized, double-blind, placebo-controlled, single-dose,
      multicenter study to evaluate the efficacy of FX-322, administered by intratympanic
      injection, in adults with acquired sensorineural hearing loss (SNHL).
    

Detailed description: 
      This is a Phase 2, prospective, randomized, double-blind, placebo-controlled, single-dose,
      multicenter study to evaluate the efficacy of FX-322, administered by intratympanic
      injection, in adults with acquired sensorineural hearing loss (SNHL).

      Previous human studies in subjects 18 to 65 years inclusive (FX-322-103, FX-322-201,
      FX-322-111) and subjects 66-85 inclusive (FX-322-112) demonstrated that a single dose FX-322
      was well tolerated in patients with acquired SNHL with no treatment-related serious adverse
      events. Adverse events in these studies were generally common to and associated with the
      intratympanic injection procedure with mild and transient discomfort in patients both with
      the drug and the placebo.

      Frequency Therapeutics' Investigators intend to evaluate efficacy with a single dose of
      FX-322 in subjects 18 to 65 years inclusive with acquired SNHL.
    

Intervention name(s): FX-322; Placebo
Intervention type(s): Drug; Drug
Intervention description(s): Active Comparator; Placebo
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: Intratympanic administration; Restoration of hearing loss
A Clinical Study of Xin'an Medicine in the Treatment of Bi Syndrome
Condition: Rheumatoid Arthritis
MeSH terms: Arthritis; Arthritis, Rheumatoid
Study type: Interventional

Summary: 
      Bi Syndrome is one of Traditional Chinese Medicine（TCM）name, It means an obstruction in
      Chinese,and it refers the syndrome characterized by the obstruction of qi and blood in the
      meridians due to the invasion of external pathogenic wind,cold and dampness, manifested as
      soreness, pain, numb,etc. Bi Syndrome contains Rheumatoid arthritis(RA). RA is a chronic
      disease affecting more than 20 million people in the world.It is one of the most common forms
      of autoimmune disease. Xin'an Medicine is one of Traditional Chinese Medicine which
      originated from AnHui. Xinfeng Capsule developed according to the Xin'an medicine theory ,and
      it has long been adopted for treatment of rheumatoid arthritis (RA). The study is aimed to
      evaluate the effectiveness and safety of Xinfeng Capsule in the treatment of RA.
    


Intervention name(s): Xinfeng capsule; leflunomide
Intervention type(s): Drug; Drug
Intervention description(s): Xinfeng capsule:Three each time, 3 times a day, Oral,for 3 months; placebo(for leflunomide):10mg each time, 1 time a day, Oral,for 3 months; Participants will continue on the stable dose of glucocorticoids and NSAIDs that they were receiving prior to study entry; leflunomide :10mg each time, one time a day, Oral,for 3 months; placebo(for xinfeng capsule):Three each time, 3 times a day, Oral,for 3 months; Participants will continue on the stable dose of glucocorticoids and NSAIDs that they were receiving prior to study entry
Intervention MeSH terms: Leflunomide
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: xinfeng capsule;; rheumatoid arthritis (RA);; randomized;; double-blind;
Therapeutic Schools: Affect Management and HIV Prevention
Condition: HIV Infections
MeSH terms: HIV Infections
Study type: Interventional
Phase: Phase 1

Summary: 
      Adolescents are at risk for HIV because of sexual and drug behavior intiated during this
      developmental period. Those with psychological distress are less likely than their peers to
      benefit from frequently used skills-based interventions. It appears that emotional lability
      during sexual situations disrupts skills learned. This project will implement and evaluate
      interventions for adolescents with psychiatric disorders who are in therapeutic school
      settings. Affect management and skills-based interventions will be compared to a didactic
      standard of care condition to determine which intervention best reduces risk behavior among
      adolescents with psychiatric disorders in therapeutic school settings.
    


Intervention name(s): Affect Management; HIV Prevention Skills; General Health Promotion
Intervention type(s): Behavioral; Behavioral; Behavioral
Intervention description(s): 12-session group intervention including affect management training as well as sexual health skills training.; 12-session group intervention including sexual health skills training.; 12-session group intervention including health information on a variety of health topics.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Prevention
Keywords: HIV prevention; HIV seronegativity
Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas
Condition: Basal Cell Nevus Syndrome; Gorlin's Syndrome
MeSH terms: Carcinoma; Carcinoma, Basal Cell; Basal Cell Nevus Syndrome; Syndrome
Study type: Interventional
Phase: Phase 2

Summary: 
      The purpose of this study is to evaluate and compare the safety and efficacy of intermittent
      vismodegib and of Photodynamic Therapy (PDT).
    

Detailed description: 
      This is a Phase II, 28 month, randomized, two arm multicenter clinical study design. During
      the initial 7 months of the study, all 24 subjects will receive vismodegib, 150mg/day. They
      then will be randomized in a 1:1 ratio to receive intermittent vismodegib, 150 mg/day, during
      months 10-13, 16-19, and 22-25 or to receive treatment with PDT at month 10 and at three
      month intervals thereafter. The safety and efficacy of intermittent vismodegib and of PDT
      will be assessed at the time of the subjects' visits to the Study Center and at the time of
      telephone contacts. A Data Safety Monitoring Board (DSMB) will review results for an interim
      analysis when 12 subjects have completed 28 months. The DSMB review will focus on adverse
      events and efficacy results. Subjects will be monitored for the presence of surrogate
      endpoint biomarkers (SEBs) at each Study visit.
    

Intervention name(s): Vismodegib; Aminolevulinic acid %20 topical solution
Intervention type(s): Drug; Drug
Intervention description(s): 150 mg per day for 7 continuous months then randomized for 3 month intervals to 28 months.; 20% topical solution applied every three months from month 10, 13, 16, 19, 22. Applied and incubated for three hours.
Other intervention name(s): Erivedge; GDC-0449; Levulan
Intervention MeSH terms: Aminolevulinic Acid
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Basal Cell Carcinoma; Photodynamic Therapy
mCVI Pilot Study: Algorithm Verification
Condition: Algorithm Verification
Study type: Observational

Summary: 
      This single center pilot study is to verify the algorithm of mCVI® to accurately capture
      pulse rate and respiratory rate in 10 healthy subjects in comparison to
      commercially-available Masimo pulse oximeter devices. This is a non significant risk device.
    

Detailed description: 
      In this pilot study the mCVI device is a mobile application used to simply verify the
      algorithm when the mobile video reads a patients pulse rate and respiratory rate while
      spontaneously breathing. There is no facial recognition technology. There is no immediate
      feedback given to the research team to act upon or provide for further clinical care
      decisions. In real time, the mCVI device will be compared to two commercially available pulse
      oximeter devices in a single visit.
    

Intervention name(s): There is no intervention
Intervention type(s): Other
Intervention description(s): There is no intervention
Observational model: Other
Time perspective: Prospective
Sampling method: Non-Probability Sample
Study population: 
        Healthy volunteers
Effect Of Calcitriol On Neutrophil To Lymphocytes Ratio And High Sensitivity C-Reactive Protein Covid-19 Patients
Condition: COVID-19
MeSH terms: COVID-19
Study type: Interventional
Phase: Phase 2

Summary: 
      This research is a study that compares the administration of calcitriol with the outcomes of
      COVID-19 patients
    

Detailed description: 
      This research was an observational analytic cohort retrospective study in which the subjects
      were moderate degree COVID-19 inpatients in Sebelas Maret University Hospital divided into
      two groups. The control group received standard therapy, while the treatment group received
      calcitriol 2x400 iu per day.
    

Intervention name(s): Calcitriol; Placebo
Intervention type(s): Drug; Other
Intervention description(s): The treatment group received calcitriol 2x400 iu per day for five days. Calcitriol uses Oscal, obtained from Kalbe Pharma; Placebo give 2x1 per day for five day
Other intervention name(s): Oscal
Intervention MeSH terms: Calcitriol
Allocation: Randomized
Intervention model: Parallel Assignment
Intervention model description: This research was an observational analytic cohort retrospective study in which the subjects were moderate degree COVID-19 inpatients in Sebelas Maret University Hospital divided into two groups. The control group received standard therapy, while the treatment group received calcitriol 2x400 iu per day.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: calcitriol, HsCRP
Early Debridement Within 24 Hours After Surgery for Wound Healing of Abdominal Incision
Condition: Surgical Wound
MeSH terms: Wounds and Injuries; Surgical Wound
Study type: Interventional

Summary: 
      Wound healing after surgery is a complex procedure. Liquefaction of the fat and necrosis of
      inactivated tissue, as well as blood clots are always accumulated mostly within 24 hours
      after surgery. As such, early debridement within 24 hours after surgery might improve the
      healing of the wounds. This study is designed to compare the impact of early debridement of
      the wound versus regular dressing (24 hours later) on the wound healing. 100 patients will be
      included in this study, and divided into 2 groups randomly. Then, the healing of the wound,
      stitch removal time, incidence of incision complications will be compared between the two
      groups.
    


Intervention name(s): Debridement Within 24 Hours After Surgery
Intervention type(s): Behavioral
Intervention description(s): Debrided within 24 hours after surgery
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Surgical Wound; Suture, Complication
Cefpodoxime vs Ciprofloxacin for Acute Cystitis
Condition: Urinary Tract Infection
MeSH terms: Urinary Tract Infections; Cystitis
Study type: Interventional

Summary: 
      Urinary tract infection (UTI) is a very common problem in young healthy women, afflicting
      approximately one-half of women by their late 20s. One of the most common antibiotics used to
      treat UTIs is ciprofloxacin, usually for a total of three days. However, increasing
      resistance to this antibiotic has raised concerns about its overuse for cystitis and
      generated interest in alternative agents. An alternative antibiotic which is approved for use
      in UTIs is cefpodoxime. However, there are few studies evaluating the efficacy and tolerance
      of this compound when given in a 3-day regimen as is commonly used for treatment of UTI. The
      major purpose of this study is to assess the efficacy and tolerance of a 3-day regimen of
      cefpodoxime versus ciprofloxacin for treatment of acute uncomplicated cystitis.
    

Detailed description: 
      Procedures subjects will undergo once they have read and signed the consent are:

      Questions about their medical and sexual history and current symptoms of UTI. They will be
      asked to provide a urine and peri-urethral sample and then are randomly assigned to one of
      the two treatment groups.They will be given a sheet to record symptoms at home. They will be
      asked to return to the clinic in 5-9 and 28-30 days after completing antibiotic
      therapy.Follow-up questions will be asked and urine and peri-urethral will be self collected
      at each visit.
    

Intervention name(s): Cefpodoxime; Ciprofloxacin
Intervention type(s): Drug; Drug
Intervention description(s): Cefpodoxime 100mg twice a day(BID)for 3 days; Ciprofloxacin 250mg twice a day (BID)for 3 days
Intervention MeSH terms: Ciprofloxacin; Cefpodoxime; Cefpodoxime proxetil
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary purpose: Treatment
Keywords: UTI
Renal HYPODYSPLASIA : Genetic and Familial Assessment
Condition: Renal HYPODYSPLASIA, Nonsyndromic, 1
MeSH terms: Kidney Diseases
Study type: Observational

Summary: 
      Evaluation of the frequency of familial cases of renal HYPODYSPLASIA
    

Detailed description: 
      DNA collection from the propositus and its family. A questionnaire will be filled by the
      parents to seek other affected individual in the family.With another affected member, DNA
      collection will be collected from the whole family.

      A renal ultrasound will be prescribed for the parents, brothers and sisters.
    

Observational model: Cohort
Sampling method: Non-Probability Sample
Study population: 
        Children with a bilateral renal hypodysplasia
      
Biospecimen description: 
      DNA collection from the propositus and its parents and in case of families with more than one
      affected member, collection of DNA from the all family.
Impact of Hepatic Impairment on the Pharmacokinetics of Deferasirox.
Condition: Hepatic Impairment
MeSH terms: Liver Diseases
Study type: Interventional
Phase: Phase 1

Summary: 
      This study is to assess the pharmacokinetics of deferasirox in hepatically impaired patients
      compared to healthy volunteers.
    


Intervention name(s): Deferasirox
Intervention type(s): Drug
Intervention description(s): one dose of 20 mg/kg/day
Other intervention name(s): ICL670
Intervention MeSH terms: Deferasirox
Allocation: Non-Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Hepatic impairment; adults; deferasirox
Effects of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Hormonal Responses to Macronutrient Ingestion
Condition: Healthy; Type 2 Diabetes
Study type: Interventional
Phase: Phase 4

Summary: 
      The regulation by DPP-4 inhibition after ingested of different individual macronutrients is
      not known. Therefore, this study examines the influence of ingestion of fat, protein, glucose
      or mixed meal on the concentrations of incretin hormones and insulin secretion with or
      without concomitant administration of a DPP-4 inhibitor (sitagliptin).
    

Detailed description: 
      Meal ingestion releases gut hormones which stimulate insulin secretion. A most important gut
      hormone is the incretin hormone glucagon-like peptide-1 (GLP-1). GLP-1 is rapidly degraded
      and inactivated after its release by the enzyme dipeptidyl peptidase-4 (DPP-4). Inhibition of
      DPP-4 therefore increases the concentration of active GLP-1 after meal ingestion, which
      augments insulin secretion. How this process is regulated after ingested of different
      individual macronutrients is not known. Therefore, this study examines the influence of
      ingestion of fat, protein, glucose or mixed meal on the concentrations of incretin hormones
      and insulin secretion with or without concomitant administration of a DPP-4 inhibitor
      (sitagliptin).
    

Intervention name(s): Sitagliptin; placebo
Intervention type(s): Drug; Drug
Intervention description(s): 100 mg sitagliptin before ingestion of macronutrient; A placebo tablet is given before ingestion of macronutrients
Other intervention name(s): Januvia
Intervention MeSH terms: Sitagliptin Phosphate
Allocation: Non-Randomized
Intervention model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Basic Science
Keywords: GLP-1; Insulin secretion; Macronutrients